Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003740733> ?p ?o ?g. }
- W2003740733 endingPage "1487" @default.
- W2003740733 startingPage "1479" @default.
- W2003740733 abstract "Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise incurable and fatal diseases, transplantation itself can lead to life-threatening complications due to organ damage. Pulmonary complications remain a significant barrier to the success of allo-HSCT. Lung injury, a frequent complication after allo-HSCT, and noninfectious pulmonary deaths account for a significant proportion of non-relapse mortality. Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating complication. BOS is now considered a diagnostic criterion of chronic graft-versus-host-disease (cGVHD), and National Institutes of Health (NIH) consensus has been published to establish guidelines for diagnosis and monitoring of BOS. It usually occurs within the first 2 years but may develop as late as 5 years after transplantation. Recent prevalence estimates suggest that BOS is likely underdiagnosed, and when severe BOS does occur, current treatments have been largely ineffective. Prevention and effective novel approaches remain the primary tools in the clinician's arsenal in managing BOS. This article provides an overview of the currently available and novel strategies for BOS, and we also discuss specific preventive interventions to reduce severe BOS after allo-HSCT. Therapeutic trials continue to be needed for this orphan disease. Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise incurable and fatal diseases, transplantation itself can lead to life-threatening complications due to organ damage. Pulmonary complications remain a significant barrier to the success of allo-HSCT. Lung injury, a frequent complication after allo-HSCT, and noninfectious pulmonary deaths account for a significant proportion of non-relapse mortality. Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating complication. BOS is now considered a diagnostic criterion of chronic graft-versus-host-disease (cGVHD), and National Institutes of Health (NIH) consensus has been published to establish guidelines for diagnosis and monitoring of BOS. It usually occurs within the first 2 years but may develop as late as 5 years after transplantation. Recent prevalence estimates suggest that BOS is likely underdiagnosed, and when severe BOS does occur, current treatments have been largely ineffective. Prevention and effective novel approaches remain the primary tools in the clinician's arsenal in managing BOS. This article provides an overview of the currently available and novel strategies for BOS, and we also discuss specific preventive interventions to reduce severe BOS after allo-HSCT. Therapeutic trials continue to be needed for this orphan disease." @default.
- W2003740733 created "2016-06-24" @default.
- W2003740733 creator A5006178388 @default.
- W2003740733 creator A5070008988 @default.
- W2003740733 creator A5087070806 @default.
- W2003740733 creator A5088962035 @default.
- W2003740733 date "2012-10-01" @default.
- W2003740733 modified "2023-10-16" @default.
- W2003740733 title "Time to Explore Preventive and Novel Therapies for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation" @default.
- W2003740733 cites W1562876511 @default.
- W2003740733 cites W1884486122 @default.
- W2003740733 cites W1963729139 @default.
- W2003740733 cites W1966121050 @default.
- W2003740733 cites W1967659869 @default.
- W2003740733 cites W1970709922 @default.
- W2003740733 cites W1971181528 @default.
- W2003740733 cites W1977166918 @default.
- W2003740733 cites W1979916062 @default.
- W2003740733 cites W1980735877 @default.
- W2003740733 cites W1983186608 @default.
- W2003740733 cites W1984164701 @default.
- W2003740733 cites W1992729068 @default.
- W2003740733 cites W1995326684 @default.
- W2003740733 cites W1996893745 @default.
- W2003740733 cites W2003007355 @default.
- W2003740733 cites W2005490939 @default.
- W2003740733 cites W2006493080 @default.
- W2003740733 cites W2006865672 @default.
- W2003740733 cites W2013426040 @default.
- W2003740733 cites W2017308096 @default.
- W2003740733 cites W2019023888 @default.
- W2003740733 cites W2019250368 @default.
- W2003740733 cites W2020828534 @default.
- W2003740733 cites W2024855035 @default.
- W2003740733 cites W2025521389 @default.
- W2003740733 cites W2026618601 @default.
- W2003740733 cites W2030439313 @default.
- W2003740733 cites W2032088650 @default.
- W2003740733 cites W2037182528 @default.
- W2003740733 cites W2039189051 @default.
- W2003740733 cites W2040403729 @default.
- W2003740733 cites W2041548911 @default.
- W2003740733 cites W2041652878 @default.
- W2003740733 cites W2042030389 @default.
- W2003740733 cites W2042594310 @default.
- W2003740733 cites W2047175700 @default.
- W2003740733 cites W2055216460 @default.
- W2003740733 cites W2061061720 @default.
- W2003740733 cites W2066883507 @default.
- W2003740733 cites W2067430956 @default.
- W2003740733 cites W2067977038 @default.
- W2003740733 cites W2069937776 @default.
- W2003740733 cites W2070374105 @default.
- W2003740733 cites W2074053390 @default.
- W2003740733 cites W2074934117 @default.
- W2003740733 cites W2076326759 @default.
- W2003740733 cites W2077127271 @default.
- W2003740733 cites W2077627992 @default.
- W2003740733 cites W2081436125 @default.
- W2003740733 cites W2084777878 @default.
- W2003740733 cites W2089422744 @default.
- W2003740733 cites W2089622680 @default.
- W2003740733 cites W2091948774 @default.
- W2003740733 cites W2094944640 @default.
- W2003740733 cites W2097470232 @default.
- W2003740733 cites W2101175123 @default.
- W2003740733 cites W2104082131 @default.
- W2003740733 cites W2110395869 @default.
- W2003740733 cites W2112046799 @default.
- W2003740733 cites W2115591184 @default.
- W2003740733 cites W2125020916 @default.
- W2003740733 cites W2130226749 @default.
- W2003740733 cites W2133590829 @default.
- W2003740733 cites W2143296077 @default.
- W2003740733 cites W2146425185 @default.
- W2003740733 cites W2148910850 @default.
- W2003740733 cites W2153309342 @default.
- W2003740733 cites W2155616447 @default.
- W2003740733 cites W2157397935 @default.
- W2003740733 cites W2163847512 @default.
- W2003740733 cites W2164136965 @default.
- W2003740733 cites W2165191569 @default.
- W2003740733 cites W2618073389 @default.
- W2003740733 doi "https://doi.org/10.1016/j.bbmt.2012.03.008" @default.
- W2003740733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22449611" @default.
- W2003740733 hasPublicationYear "2012" @default.
- W2003740733 type Work @default.
- W2003740733 sameAs 2003740733 @default.
- W2003740733 citedByCount "22" @default.
- W2003740733 countsByYear W20037407332012 @default.
- W2003740733 countsByYear W20037407332013 @default.
- W2003740733 countsByYear W20037407332014 @default.
- W2003740733 countsByYear W20037407332015 @default.
- W2003740733 countsByYear W20037407332016 @default.
- W2003740733 countsByYear W20037407332017 @default.
- W2003740733 countsByYear W20037407332018 @default.
- W2003740733 countsByYear W20037407332021 @default.
- W2003740733 countsByYear W20037407332023 @default.